Global Belumosudil Tablet Market Size, Share & Trends Analysis Report By Indication (Chronic Graft-versus-Host Disease, Systemic Sclerosis, Idiopathic Pulmonary Fibrosis, Other Fibrotic Conditions), By Line of Treatment (Second-Line, Third-Line & Beyond, Salvage Therapy), By Patient Demographics (Adults, Pediatrics), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies), By End-User (Hospitals & Transplant Centers, Specialty Oncology Clinics, Academic Medical Centers), and By Region (North America, Europe, APAC, Middle East & Africa, LATAM) - Forecasts, 2026-2034.

Table of Contents

1. Introduction

1.1. Market Introduction
1.2. Research Methodology
1.3. Market Definition & Scope
1.4. Assumptions and Limitations
1.5. Stakeholder Analysis
1.6. Key Takeaways

2. Executive Summary

2.1. Market Snapshot, 2025–2034
2.2. Key Findings by Indication
2.3. Key Findings by Treatment Line
2.4. Key Findings by Patient Demographics
2.5. Key Findings by Region
2.6. Strategic Outlook

3. Global Belumosudil Tablet Market Insights

3.1. Market Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.2. Market Restraints
3.2.3. Market Opportunities
3.2.4. Market Challenges

3.3. Market Ecosystem Analysis
3.4. Value Chain Analysis
3.5. Pricing Analysis
3.6. Regulatory Landscape Analysis
3.7. Reimbursement Scenario Analysis
3.8. Clinical Development & Pipeline Analysis
3.9. Treatment Algorithm & Sequencing Analysis
3.10. Patent and Exclusivity Assessment
3.11. Porter’s Five Forces Analysis
3.12. PESTEL Analysis

4. Market Size & Forecast Analysis (USD Million), 2022–2034

4.1. Global Market Revenue Analysis
4.2. CAGR Analysis by Segment
4.3. Absolute Dollar Opportunity Analysis
4.4. Market Attractiveness Analysis

5. Global Belumosudil Tablet Market, By Indication

5.1. Overview & Market Share Analysis

5.2. Chronic Graft-versus-Host Disease (cGVHD)
5.2.1. Sclerotic Skin Manifestations
5.2.2. Bronchiolitis Obliterans Syndrome
5.2.3. Hepatic Involvement
5.2.4. Gastrointestinal Manifestations
5.2.5. Multi-Organ Disease

5.3. Systemic Sclerosis
5.4. Idiopathic Pulmonary Fibrosis
5.5. Other Fibrotic Conditions
5.5.1. Primary Biliary Cholangitis
5.5.2. Non-Alcoholic Steatohepatitis (NASH)

6. Global Belumosudil Tablet Market, By Line of Treatment

6.1. Overview & Market Share Analysis
6.2. Second-Line Therapy
6.3. Third-Line & Beyond Therapy
6.4. Salvage Therapy
6.5. Combination Therapy Settings

7. Global Belumosudil Tablet Market, By Patient Demographics

7.1. Overview & Market Share Analysis
7.2. Adults (18 Years and Older)
7.3. Pediatrics (12–17 Years)
7.4. Emerging Pediatric Use (<12 Years)

8. Global Belumosudil Tablet Market, By Distribution Channel

8.1. Overview & Market Share Analysis
8.2. Hospital Pharmacies
8.3. Specialty Pharmacies
8.4. Online Pharmacies
8.5. Government Procurement Programs

9. Global Belumosudil Tablet Market, By End-User

9.1. Overview & Market Share Analysis
9.2. Hospitals & Transplant Centers
9.3. Academic Medical Centers
9.4. Specialty Oncology Clinics
9.5. Ambulatory Care Centers
9.6. Research Institutions

10. Global Belumosudil Tablet Market, By Region

10.1. Regional Market Overview

10.2. North America
10.2.1. United States
10.2.2. Canada
10.2.3. Mexico

10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Netherlands
10.3.7. Rest of Europe

10.4. Asia Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. South Korea
10.4.5. Australia
10.4.6. Rest of Asia Pacific

10.5. Middle East & Africa
10.5.1. Saudi Arabia
10.5.2. UAE
10.5.3. South Africa
10.5.4. Rest of Middle East & Africa

10.6. Latin America
10.6.1. Brazil
10.6.2. Argentina
10.6.3. Rest of Latin America

11. Competitive Landscape

11.1. Market Share Analysis, 2025
11.2. Competitive Benchmarking
11.3. Strategic Developments Analysis
11.4. Mergers & Acquisitions
11.5. Product Launches & Label Expansions
11.6. Clinical Trial & Pipeline Activity

12. Company Profiles

12.1. Sanofi SA (Kadmon Holdings)
12.2. Incyte Corporation
12.3. Syndax Pharmaceuticals Inc.
12.4. Novartis AG
12.5. Bristol Myers Squibb Company
12.6. Pfizer Inc.
12.7. AstraZeneca PLC
12.8. Johnson & Johnson (Janssen)
12.9. Astellas Pharma Inc.
12.10. Rigel Pharmaceuticals Inc.
12.11. Equillium Inc.
12.12. Mallinckrodt Pharmaceuticals
12.13. Biocad
12.14. Takeda Pharmaceutical Company
12.15. AbbVie Inc.

(Each profile includes Company Overview, Financial Overview, Product Portfolio, Business Strategy, Recent Developments, and SWOT Analysis.)

13. Emerging Market Trends & Future Outlook

13.1. ROCK2 Inhibitor Innovation Landscape
13.2. Biomarker-Driven Precision Medicine Trends
13.3. Fibrotic Disease Expansion Opportunities
13.4. Pediatric Market Expansion Outlook
13.5. Future Market Projections and Strategic Recommendations

14. Appendix

14.1. Abbreviations
14.2. Research Assumptions
14.3. List of Tables
14.4. List of Figures
14.5. References & Data Sources